secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001384101-24-000064
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q1 revenue $96.8M (+17%), testing revenue +25%, net loss narrows 77%
-----------------------------------------------------------------------------

- Total revenue $96.8M (up 17% YoY); testing revenue $90.3M (up 25%) led by Decipher Prostate and Afirma.
- Net loss improved 77% to $1.9M ($0.02 per share) from $8.3M loss in Q1 2023.
- Non-GAAP gross margin held at 68%; non-GAAP op expenses grew 6% to $61.6M.
- Decipher Prostate received highest NCCN rating; contracted with large commercial payer covering ~30M members.
- Completed C2i Genomics acquisition for MRD testing; initiated bladder cancer MRD test; cash $209.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/0001384101-24-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410124000064/vcyt-20240507.htm
  HTML page:      https://secwatch.observer/filing/0001384101-24-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer